*Current as of May 2022.
Emerging Therapeutics=currently being studied in clinical trials; Evolving Therapeutics=either proof-of-concept studies or in a very early clinical stage. ALK=anaplastic lymphoma kinase; BRAF=B-Raf proto-oncogene; EGFR=endothelial growth factor receptor; ERBB2=receptor tyrosine kinase ErbB2 (human EGF receptor 2 or HER2); KRAS=Kirsten rat sarcoma; MET=MET proto-oncogene; mNSCLC=metastatic non–small cell lung cancer; NTRK=neurotrophic tyrosine receptor kinase; RET+=rearranged during transfection positive; ROS1=ROS proto-oncogene 1.
Comprehensive biomarker testing can assess most actionable biomarkers with one test—so you can identify which biomarker may be responsible for driving disease5
The National Comprehensive Cancer Network® (NCCN®) NSCLC Panel recommends that eligible patients with metastatic NSCLC receive routine biomarker testing for2:
NGS-based tissue genotyping and plasma ctDNA testing are considered accurate, reliable, and complementary approaches to test for actionable biomarkers, including RET alterations.6
IASLC Guidelines6
Plasma ctDNA can now be considered a valid tool for genotyping of newly diagnosed patients with advanced NSCLC and should be performed using a clinically validated NGS platform
NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®)2
NCCN Guidelines® recommend plasma ctDNA testing as an option when there is limited tissue availability or the patient is unfit for invasive tissue sampling
The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
ctDNA=circulating tumor DNA; IASLC=International Association for the Study of Lung Cancer; NCCN=National Comprehensive Cancer Network® (NCCN®); NGS=next generation sequencing; PD-L1=programmed death-ligand 1; QNS=quality not sufficient.
Reviewing biomarker test results before initiating treatment could help determine an appropriate treatment plan8
Blueprint Medicines Corporation and Genentech, Inc. are not responsible for any information, statements, or other content you may encounter on third-party websites.
Blueprint Medicines Corporation and Genentech, Inc. are not responsible for any information, statements, or other content you may encounter on third-party websites.